

Product Disclaimer and Terms: Database of Stem Cell Treatment Providers (400+ Clinics), 2024

The companies, people, and/or products and services included in the “Database of Stem Cell Treatment Providers (400+ Clinics), 2024” (the “Product”), published by BioInformant Worldwide, L.L.C. (“BioInformant”), are for **informational purposes only**. The clinics and providers listed in this Product are **not** endorsed by BioInformant and have **not** been evaluated by the U.S. FDA. Their practices may not comply with the U.S. FDA and/or other regulatory bodies worldwide.

Information contained within this Product is **not** expressed as medical claims or advice. This Product is **not** intended to diagnose, treat, cure or prevent any disease or condition.

This database is **not** intended to be used by patients or members of the public, but **solely to provide market data to industry professionals**, specifically biotech and medical device executives, medical professionals, and industry regulators.

To learn more about the risks, dangers, and adverse events associated with stem cells, please review the following U.S. FDA warnings about stem cell therapies and other regenerative therapies at the links below:

1. [Important Patient and Consumer Information About Regenerative Medicine Therapies](#)
2. [Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes](#)

Additionally, you may report negative outcomes or dangers of regenerative medicine products, including, for example, stem cell products and exosome products, to the FDA’s [MedWatch Adverse Event Reporting](#) program.

As stated by the [U.S. FDA at this page](#):

“The US Food and Drug Administration (FDA) regulates regenerative medicine products. There continues to be broad marketing of unapproved products considered regenerative medicine therapies that are intended for the treatment or cure of a wide range of diseases or medical conditions. These products require FDA licensure/approval to be marketed to consumers. Before approval, these products require FDA oversight in a clinical trial. These unapproved products whether recovered from your own body or another person’s body, include stem cells, stromal vascular fraction (fat-derived cells), umbilical cord blood and/or cord blood stem cells¹, amniotic fluid, Wharton’s jelly, orthobiologics, and [exosomes](#). FDA has received reports of blindness, tumor formation, infections, and more, detailed below, due to the use of these unapproved products.

If you are being offered any of these products outside of a clinical trial for which FDA has oversight, please contact FDA at ocod@fda.hhs.gov. Additionally, contact FDA if you are considering treatment with any of these products and have questions, or if you have been treated with these products and wish to report any adverse effects or file a complaint. We take these reports seriously and want to hear from you.

If you were hurt or had a bad side effect following treatment with a regenerative medicine product, or a similar product, we also encourage you to report it to the [FDA’s MedWatch Adverse Event Reporting program](#). Additional information for patients on reporting adverse events for these products can be found [here](#).

Please know that if you are being charged for these products or offered these products outside of a clinical trial, you are likely being deceived and offered a product illegally. Likewise, FDA is aware that patients and consumers are being referred to clinicaltrials.gov, or are told that a product is registered with FDA, as a way to suggest that the products being offered are in compliance with FDA laws and regulations. This is often false. The inclusion of a product in the clinicaltrials.gov database or the fact that a firm has registered with FDA and listed its product does not mean the product is legally marketed. If you are considering receiving one of these products, please contact FDA at ocod@fda.hhs.gov.”

Source: <https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies>

Given these risks, if you have a health condition or concern, you must consult with your physician or other licensed healthcare provider. You may also contact the U.S. FDA with your questions/concerns about stem cells, exosomes, or other regenerative therapies.

Finally, you must use this Product in compliance with BioInformant’s License Terms, which permit an individual (the “Purchaser”) to view and print this Product. You are **not** permitted to duplicate, alter, sell, send, or share this Product with any other individual, company, entity, or organization.

If anything stated above conflicts with your needs or intended use, please contact Info@BioInformant.com to be issued a full refund under BioInformant’s 60-Day Money Back Guarantee.